EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma

Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana Arance, Jan Willem B de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai und 8 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114073 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Dirk Schadendorf und 19 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Essen, West German Cancer Center and German Cancer Consortium, Partner Site Essen, Essen, Germany; National Center for Tumor Dise…. Hauptthemen laut MEDLINE: Melanoma, Carbamates, Proto-Oncogene Proteins B-raf, Sulfonamides. Die Arbeit wurde bisher 89-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Array Biopharma Inc, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaCarbamatesProto-Oncogene Proteins B-rafSulfonamidesBenzimidazolesAntineoplastic Combined Chemotherapy ProtocolsVemurafenibMutationHumansMaleFemaleMiddle AgedAgedAdultSkin NeoplasmsAged, 80 and overProgression-Free SurvivalYoung Adult

Stichwörter der Autor:innen

BRAF-mutantBinimetinibEncorafenibMelanoma

Substanzen

CarbamatesProto-Oncogene Proteins B-rafSulfonamidesBenzimidazolesVemurafenibencorafenibbinimetinibBRAF protein, human

Autor:innen und Institutionen

  • University Hospital Essen, West German Cancer Center and German Cancer Consortium, Partner Site Essen, Essen, Germany; National Center for Tumor Diseases West, Campus Essen, and Research Alliance Ruhr, Research Center O…
  • University Hospital Zurich, Zurich, Switzerland.
  • Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Gustave Roussy and Paris-Saclay University, Villejuif, France.
  • Hospital Clinic of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Isala Oncology Center, Zwolle, the Netherlands.

Förderung

  • Array Biopharma Inc
  • Pfizer

Zitieren

APA

Schadendorf, D., Dummer, R., Flaherty, K. T., Robert, C., Arance, A., de Groot, J. W. B., Garbe, C., Gogas, H. J., Gutzmer, R., Krajsová, I., Liszkay, G., Loquai, C., Mandalà, M., Yamazaki, N., Queirolo, P., Guenzel, C., Polli, A., Thakur, M., di Pietro, A., & Ascierto, P. A. (2024). COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114073

Vancouver

Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, et al. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114073

BibTeX
@article{Schadendorf2024,
  author = {Schadendorf, Dirk and Dummer, Reinhard and Flaherty, Keith T and Robert, Caroline and Arance, Ana and de Groot, Jan Willem B and Garbe, Claus and Gogas, Helen J and Gutzmer, Ralf and Krajsová, Ivana and Liszkay, Gabriella and Loquai, Carmen and Mandalà, Mario and Yamazaki, Naoya and Queirolo, Paola and Guenzel, Carolin and Polli, Anna and Thakur, Mahgull and di Pietro, Alessandra and Ascierto, Paolo A},
  title = {COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114073}
}
Kostenlos starten →